US FDA limits use of Regeneron, Lilly COVID-19 antibody treatments

The highly contagious new variant was estimated to account for more than 99 per cent of cases in the United States as of Jan 15.

GSK and Vir Biotech are boosting production of their drug, sotrovimab to help meet soaring demand in the United States. The FDA has also expanded its approval for the use of Gilead Sciences’ antiviral COVID-19 drug remdesivir to treat non-hospitalised patients aged 12 years and above.

The Washington Post earlier in the day reported that the FDA was expected to revise authorisations for Regeneron and Lilly’s treatments.

A Regeneron spokesperson had said the regulator would provide any potential communication on the topic.

Lilly had no immediate comment but pointed to its statement from December saying its antibody candidate, bebtelovimab, maintains neutralisation activity against all known variants of concern, including Omicron.


This website uses cookies. By continuing to use this site, you accept our use of cookies.